{"product_id":"companion-diagnostic-testing-for-non-small-cell-lung-cancer","title":"Companion Diagnostic Testing for Non-Small Cell Lung Cancer","description":"\u003cp\u003eLung cancer is a malignancy of epidemic proportions.  In the United States, it is estimated that there will be more than 228,000 new cases of lunch cancer each year, with 40% of those presenting with Stage IV metastatic disease.  Non-small cell lung cancers (NSCLC) make up approximately 70% of all lung cancers diagnosed.  Ongoing advancements in medicine are raising the bar in oncology management, including NSCLCs.  Data show that patients respond differently to the\n\u003cbr\u003esame drug. By identifying a sub-group of patients most likely to benefit from a specific drug therapy, patients can be confident that their treatment will provide optimal responses. A companion\n\u003cbr\u003ediagnostic enables personalized healthcare. It is used to predict which patients are most likely to benefit from a particular therapy and\/or how best to administer a therapy to an individual. This 6 panel pocket card provides at-a-glance information about companion diagnostic testing for non-small cell lung cancers. The card concisely summarizes:  epidemiology; histology; etiology and risk factors; evaluation and staging; treatment overview; personalized treatment; companion testing; and\n\u003cbr\u003eimplications. The content is excerpted from Dr. Gary Lyman's Oxford American Handbook of Oncology.\u003c\/p\u003e","brand":"Oxford University Press","offers":[{"title":"Default Title","offer_id":46060544393454,"sku":"9780199388646","price":17.42,"currency_code":"AUD","in_stock":true}],"url":"https:\/\/bookland.com.au\/products\/companion-diagnostic-testing-for-non-small-cell-lung-cancer","provider":"Book Land AU","version":"1.0","type":"link"}